Mitsubishi Shipbuilding and INPEX Complete Conceptual Study for Ammonia Bunkering Vessel
TOKYO, Feb 2, 2023 – […]
ป้ายกำกับ: study
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer’s Disease in Japan
TOKYO and CAMBRIDGE, Mass […]
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease in Europe
TOKYO, Jan 11, 2023 ̵ […]
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
ROCKVILLE, MD and SHENZHE […]
MHI Signs MoU with Chile’s Guacolda Energia for Feasibility Study of Ammonia Co-Firing at a Coal-Fired Thermal Power Plant
TOKYO, Dec 7, 2022 – […]
AJG Publishes Data from HighTide Therapeutics’ Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis
ROCKVILLE, MD and SHENZHE […]
American Journal of Gastroenterology Publishes Data from HighTide Therapeutics’ Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis
ROCKVILLE, MD and SHENZHE […]
Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon
TOKYO, Nov 2, 2022 – […]
Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA
HONG KONG, Aug 24, 2022 & […]
Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022
TOKYO, Jul 26, 2022 ̵ […]
TrialWire Technology Platform Rolls Out World First SMS/Text Patient Contact System Across all Studies Globally
ADELAIDE, AUS, Jul 20, 20 […]
Joint Feasibility Study on the Commercialization of Sustainable Aviation Fuel
TOKYO, Apr 19, 2022 ̵ […]
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting
CAMBRIDGE, Mass., and TOK […]
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
HONG KONG, Feb 7, 2022 &# […]
Eisai’s Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study
TOKYO, Jan 19, 2022 ̵ […]
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium
TOKYO, Jan 17, 2022 ̵ […]
Investigational Alzheimer’s Disease Therapy Lecanemab Granted FDA Fast Track Designation
TOKYO, Dec 24, 2021 ̵ […]
Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference
TOKYO and CAMBRIDGE, Mass […]
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin
SHANGHAI, Sep 26, 2021 &# […]
Toyota: Feasibility Study on the Receiving and Distribution Business of Imported Hydrogen in Chubu Regio
Toyota City, Japan, Aug 6 […]